The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Recently, Yahoo Finance discussed the stock, revealing that Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Highlights.
The company is listed on the NASDAQ and operates within the Drug Manufacturers – Specialty & Generic industry segment. The current market capitalization of Dynavax Technologies Corp. is $1.68B. A total of 1.4 million shares were traded on the day, compared to an average of 1.81M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, DVAX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 38 BUYs and 35 SELLs from insiders. Insiders purchased 379,011 shares during that period but sold 3,290,474.
In the most recent transaction, Janssen Robert sold 1,500 shares of DVAX for 15.00 per share on Jan 04. After the transaction, the SVP and CMO now owns 49,925 company shares. In a previous transaction on Jan 02, Novack David F sold 9,000 shares at 14.45 per share. DVAX shares that President & COO owns now total 3,187.
Among the insiders who sold shares, Novack David F disposed of 20,000 shares on Dec 01 at a per-share price of $13.56. This resulted in the President & COO holding 3,187 shares of DVAX after the transaction. In another insider transaction, Novack David F sold 20,000 shares at $15.00 per share on Nov 03. Company shares held by the President & COO now total 3,187.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for DVAX in the last 3 months, the mean price target is $24.50 with high estimates of $29.00 and low estimates of $20.00. In terms of 52-week highs and lows, DVAX has a high of $15.15 and a low of $9.42.
As of this writing, DVAX has an earnings estimate of -$0.01 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $0.01 per share and a lower estimate of -$0.03. The company reported an EPS of $0.03 in the last quarter, which was 133.30% higher than expectations of -$0.09.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. DVAX’s latest balance sheet shows that the firm has $545.95M in Cash & Short Term Investments as of fiscal 2021. There were $257.38M in debt and $556.40M in liabilities at the time. Its Book Value Per Share was $4.68, while its Total Shareholder’s Equity was $222.37M.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DVAX is Buy with a score of 4.60.